- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00600405
The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients
January 14, 2008 updated by: MaineHealth
The purpose of this study is to determine the efficacy of the α-adrenergic antagonist tamsulosin in the treatment of adult emergency department (ED) patients with ureteral colic secondary to lower ureteral calculus.
We hypothesize that there will be no difference in outcomes for subjects treated with and without tamsulosin.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This prospective, randomized controlled trial seeks to compare outcomes for adult emergency department patients with lower ureteral calculus.
Subjects will be randomized to receive treatment with ibuprofen and oxycodone alone (standard therapy) or standard therapy plus tamsulosin 0.4mg orally once daily for ten days.
Study Type
Interventional
Enrollment (Actual)
81
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maine
-
Portland, Maine, United States, 04102
- Maine Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years of age or older;
- able to read, write, and speak English;
- able to use the NRS pain scale; and
- computed tomography diagnosed single lower ureteral calculus
Exclusion Criteria:
- allergy or sensitivity to the study drug (tamsulosin hydrochloride [Flomax]);
- sulfa/sulfonamide allergy;
- inability to provide informed consent;
- lithiasis of the ureteral intramural tract;
- acute or chronic renal failure;
- fever;
- presence of multiple ureteral stones;
- peptic ulcer disease;
- liver failure;
- concomitant treatment with alpha-lytic drugs, calcium antagonists, nitrates, or vardenafil (Levitra);
- pregnancy;
- breastfeeding; or
- a history of urinary surgery or endoscopic treatment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: I
Subjects randomized to the experimental group receive ibuprofen, oxycodone, and tamsulosin 0.4 mg orally daily for ten days.
|
Tamsulosin 0.4 mg orally daily for ten days.
Other Names:
|
Other: II
Standard therapy arm: subjects randomized to standard therapy receive ibuprofen and oxycodone alone.
|
Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain.
Ibuprofen: 800 mg, one three times a day with food as needed for pain.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of spontaneous ureteral stone expulsion
Time Frame: 48, 120, 336 hours
|
48, 120, 336 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to spontaneous ureteral stone expulsion.
Time Frame: 48, 120, 336 hours
|
48, 120, 336 hours
|
Self-reported NRS-11 pain scores.
Time Frame: 48, 120, 336 hours
|
48, 120, 336 hours
|
Number of colicky pain episodes.
Time Frame: 48, 120, 336 hours
|
48, 120, 336 hours
|
Number of days missed work or usual functional ability.
Time Frame: 48, 120, 336 hours
|
48, 120, 336 hours
|
Number of return ED visits or unscheduled PCP visits for continued pain.
Time Frame: 48, 120, 336 hours
|
48, 120, 336 hours
|
Amount of narcotic pain medication used.
Time Frame: 48, 120, 336 hours
|
48, 120, 336 hours
|
Adverse medication-related events.
Time Frame: 48, 120, 336 hours
|
48, 120, 336 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Andrew D Perron, MD, MaineHealth
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2006
Primary Completion (Actual)
November 1, 2007
Study Completion (Actual)
November 1, 2007
Study Registration Dates
First Submitted
January 14, 2008
First Submitted That Met QC Criteria
January 14, 2008
First Posted (Estimate)
January 25, 2008
Study Record Updates
Last Update Posted (Estimate)
January 25, 2008
Last Update Submitted That Met QC Criteria
January 14, 2008
Last Verified
January 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Kidney Diseases
- Urologic Diseases
- Disease Attributes
- Pathological Conditions, Anatomical
- Ureteral Diseases
- Urolithiasis
- Urinary Calculi
- Emergencies
- Calculi
- Kidney Calculi
- Nephrolithiasis
- Ureteral Calculi
- Ureterolithiasis
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Urological Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Analgesics, Opioid
- Narcotics
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Ibuprofen
- Tamsulosin
- Oxycodone
Other Study ID Numbers
- 2958
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nephrolithiasis
-
Mayo ClinicCompletedNephrolithiasis, Calcium Oxalate | Nephrolithiasis, Calcium PhosphateUnited States
-
University Hospital Inselspital, BerneCompletedCalcium NephrolithiasisSwitzerland
-
University of Texas Southwestern Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)WithdrawnUric Acid NephrolithiasisUnited States
-
University of British ColumbiaRecruiting
-
University of Texas Southwestern Medical CenterRecruitingNephrolithiasis, Uric AcidUnited States
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingKidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
Mahidol UniversityNot yet recruitingSafety Issues | Surgery-Complications | Nephrolithiasis Staghorn CalculusThailand
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingHealthy | Kidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Himalaya...CompletedCystinuria | Nephrolithiasis, Calcium OxalateUnited States
-
Ai PengUnknown
Clinical Trials on tamsulosin
-
Hanmi Pharmaceutical Company LimitedCompletedBenign Prostate HyperplasiaKorea, Republic of
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedProstatic Hyperplasia
-
Menoufia UniversityCompletedProstatic Neoplasms | Prostate Disease | Prostate Hypertrophy | Prostate ObstructionEgypt
-
Lawson Health Research InstituteNot yet recruitingUrinary Retention PostoperativeCanada
-
Boehringer IngelheimCompleted
-
Samsung Medical CenterUnknown
-
Hackensack Meridian HealthRecruitingUrinary RetentionUnited States
-
Astellas Pharma China, Inc.CompletedHealthy | Pharmacokinetics of Tamsulosin HydrochlorideChina
-
CHU de Quebec-Universite LavalFédération des médecins résidents du QuébecNot yet recruitingColorectal Surgery | Urinary Retention | Post-operative Urinary Retention | Rectal Resection | TamsulosinCanada